MNOV - MediciNova, Inc. Summary, Stock Quote and News | Benzinga

Skip to main content

Market Overview

4.100 0.1 (2.5%)

Data as of May 09, 2021

Prev. Close 4
Price Open 4.02
Volume 430,467
Day's Range 4.01 - 4.15
52 Wk Range 3.9 - 13.25
50 Day Moving Avg. 5.12
PE Ratio
Shares Outstanding 48.77M
Market Cap 199.95M

Trade MNOV stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Shanthi RexalineFri, 07 May 2021 07:40:07 -0400
Stocks That Hit 52-Week Lows On Thursday Benzinga InsightsThu, 06 May 2021 10:05:03 -0400
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Shanthi RexalineWed, 05 May 2021 07:43:28 -0400
Stocks That Hit 52-Week Lows On Tuesday Benzinga InsightsTue, 04 May 2021 10:12:44 -0400
UPDATE: Zacks Article On MediciNova Gives $26.50/Share Valuation Benzinga NewsdeskMon, 26 Apr 2021 10:12:00 -0400
MediciNova Shares Move Higher After Zacks Article Highlights Co., Mentions Apr. 22 Receipt Of $4M Milestone Payments Benzinga NewsdeskMon, 26 Apr 2021 10:10:25 -0400
MediciNova Receives Gene Therapy Milestone Payments of $4M Benzinga NewsdeskThu, 22 Apr 2021 06:30:30 -0400
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Shanthi RexalineWed, 21 Apr 2021 07:31:27 -0400
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Shanthi RexalineTue, 20 Apr 2021 08:04:11 -0400
Stocks That Hit 52-Week Lows On Friday Benzinga InsightsFri, 16 Apr 2021 13:00:36 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe Globe Newswire3 days ago
MediciNova Receives Gene Therapy Milestone Payments Globe NewswireApr 22, 2021
MediciNova to Participate in the B. Riley Neuroscience Conference Globe NewswireApr 19, 2021
MediciNova to Participate in the UBS Global Healthcare Virtual Conference Globe NewswireApr 15, 2021
MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury Globe NewswireMar 09, 2021
MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference Globe NewswireMar 08, 2021
MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19 Globe NewswireMar 03, 2021
MediciNova Announces Closing of US$20 Million Private Placement Transaction Globe NewswireJan 31, 2021
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan Globe NewswireJan 18, 2021
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners Globe NewswireJan 11, 2021
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

The MediciNova Riddle: Worth Unravelling Seeking AlphaApr 26, 2021
Oracle, HSBC Holdings leads the premarket losers' pack Seeking AlphaMar 11, 2021
IPO Update: Gain Therapeutics Proposes IPO Terms Seeking AlphaMar 10, 2021
Stocks Extend Rebound as Inflation Concerns Ease TalkMarketsMar 10, 2021
GME, BLUE, EH and VBIV among premarket gainers Seeking AlphaMar 10, 2021
MNOV Stock: MediciNova Soars on Big BARDA Deal InvestorPlaceMar 10, 2021
MediciNova Jumps on BARDA partnership for Ibudilast development Seeking AlphaMar 09, 2021
Gain Therapeutics Aims For $40 Million IPO Seeking AlphaFeb 25, 2021
Vaccine Roundup: Merck Wipes Out (And More) Seeking AlphaJan 26, 2021
MediciNova nabs new Japanese patent for ibudilast + riluzole in neurodegenerative disease Seeking AlphaJan 19, 2021
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Powered by StockSnips

70.09% Positive

Earnings View Earnings

Q4 2020	EST	Actual	Surprise
EPS:	Expected 2021-02-19
Rev:	Expected 2021-02-19

Q2 2021	EST	Actual	Surprise
EPS:	Expected 2021-07-27
Rev:	Expected 2021-07-27

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses